Announcements Trials
Browse Landscape

Phase

Phase 2 6

Status

Unknown 3Completed 2Recruiting 1

Sponsor Class

OTHER 5OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Carcinoma, Hepatocellular 61Stomach Neoplasms 46Carcinoma, Non-Small-Cell Lung 37Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Lung Neoplasms 12Rectal Neoplasms 11Nasopharyngeal Carcinoma 11Esophageal Neoplasms 11Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Cholangiocarcinoma 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Liver Neoplasms 5Triple Negative Breast Neoplasms 4Recurrence 4Endometrial Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Solid Tumor 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3

Interventions

Gemcitabine 113Cisplatin 77Oxaliplatin 46pembrolizumab 35Fluorouracil 33Capecitabine 31durvalumab 27Leucovorin 27lenvatinib 26Magnetic Resonance Spectroscopy 15Irinotecan 14Drug Therapy 13Biopsy 13Nivolumab 12Albumin-Bound Paclitaxel 12tislelizumab 11Specimen Handling 11Radiofrequency Ablation 11130-nm albumin-bound paclitaxel 11pemigatinib 10apatinib 10Taxes 10Radiotherapy 10Floxuridine 10Folfox protocol 9Bevacizumab 9S 1 (combination) 8Platinum 8Photochemotherapy 8Liver Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Cholangiocarcinoma × sintilimab × Clear all
NCT05348811 2026-01-06

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Zhongda Hospital

Phase 2 Completed
25 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05010681 2025-02-27

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

Fudan University

Phase 2 Recruiting
25 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05010668 2025-02-21

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Fudan University

Phase 2 Completed
28 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Unknown
30 enrolled
Gastrointestinal

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

NCT05251662 2022-02-23

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
90 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05207735 2022-01-26

SCRCA

Henan Cancer Hospital

Phase 2 Unknown
73 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡